Please assess the completion status of the following clinical trial:

Trial Title: Study of Pharmacotherapy of Psychotic Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major depressive disorder, single or recurrent, with psychotic features~Exclusion Criteria:~* History of substance abuse or dependence within the 3 months prior to enrollment~* Acute or unstable medical illness~* Diagnosis of schizophrenia or other psychotic disorders~* Pregnant~* Intolerance to SSRIs or olanzapine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- olanzapine/sertraline combination (Type: ACTIVE_COMPARATOR): sertraline plus olanzapine
- olanzapine plus placebo (Type: PLACEBO_COMPARATOR): olanzapine (5 - 20mg/day) plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).